详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: A meta-analysis.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, China [2]Guangdong Medical University, Guangdong, China [3]Department of Dermatology, Qingyuan Hospital of Traditional Chinese Medicine, Guangdong, China

出处：

DOI：

ISSN：

关键词： enteric peritonitis gastric‐acid suppressants meta‐analysis peritoneal dialysis

摘要：

Mounting evidence suggests that long-term use of gastric-acid suppressants (GASs) may be associated with adverse effects. Whether GAS use increases the risk of enteric peritonitis in patients undergoing peritoneal dialysis (PD) is not known. The aim of this meta-analysis was to evaluate the association between GAS use and enteric peritonitis in PD patients. We searched PubMed, Embase and Cochrane Library databases from inception to 23 January 2018 to identify eligible studies. The primary outcome was an association between GAS use and enteric peritonitis in PD patients. Six studies involving 829 people were included in this meta-analysis. Pooled data showed that GAS use in PD patients was associated with an increased risk of enteric peritonitis (odds ratio [OR] = 1.27; 95% confidence interval [CI]: 1.02-1.57, I2 = 48%). Subgroup analyses based on GAS type revealed that histamine-2 receptor antagonists (H2 RAs) might increase the risk of enteric peritonitis in PD patients (OR = 1.40; 95% CI: 1.01-1.93; I2 = 8%), but proton pump inhibitors (PPIs) might not (1.13; 0.72-1.77; 6; 34%). Gastric-acid suppressants use might be a risk factor for enteric peritonitis in PD patients. In particular, H2 RAs increased the risk of enteric peritonitis, but PPIs did not. Therefore, to prevent enteric peritonitis, H2 RAs should probably be prescribed with caution for PD patients. © 2018 John Wiley & Sons Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 4 区医学

小类 | 4 区药学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区药学

第一作者：

第一作者机构： [1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, China [2]Guangdong Medical University, Guangdong, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, China [*1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Outcomes after transfer from hemodialysis to peritoneal dialysis vs peritoneal dialysis as initial therapy: A systematic review and meta-analysis. [2]Progress in research of peritoneal dialysis complicated with peritonitis [3]Increased Arterial Stiffness in Elderly Female Diabetic Peritoneal Dialysis Patients [4]Focus on peritoneal dialysis training: working to decrease peritonitis rates [5]The effect of coix seed on the nutritional status of peritoneal dialysis patients: A pilot study [6]The Peritoneal Dialysis Telemedicine-assisted Platform Cohort (PDTAP) Study: Design and methods. [7]腹膜透析相关隧道及外出口感染的原因分析 [8]CAPD Versus APD in Nondiabetic Peritoneal Dialysis Patients [9]Heart rate variability predicts mortality in peritoneal dialysis patients [10]Association of Serum Uric Acid with Arterial Stiffness in Peritoneal Dialysis Patients.